ketanest 25 mg/ ml
pfizer as - esketaminhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 25 mg/ ml
ketanest 5 mg/ ml
pfizer as - esketaminhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 5 mg/ ml
pentocur 1 g
abcur ab - tiopentalnatrium - pulver til injeksjonsvæske, oppløsning - 1 g
pentocur 0.5 g
abcur ab - tiopentalnatrium - pulver til injeksjonsvæske, oppløsning - 0.5 g
tezspire
astrazeneca ab - tezepelumab - astma - legemidler for obstruktive sykdommer i luftveiene, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
airexar spiromax
teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - airexar spiromax er indisert for bruk hos voksne i alderen 18 år og eldre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesykdom (kols)airexar spiromax er indikert for symptomatisk behandling av pasienter med kols, med en fev1.
inuxair 200 mikrog / 6 mikrog
chiesi farmaceutici s.p.a. - beklometasondipropionat / formoterolfumaratdihydrat - inhalasjonsaerosol, oppløsning - 200 mikrog / 6 mikrog
ketamin abcur 10 mg/ ml
abcur ab - ketaminhydroklorid - injeksjonsvæske, oppløsning - 10 mg/ ml
ketamin abcur 50 mg/ ml
abcur ab - ketaminhydroklorid - injeksjonsvæske, oppløsning - 50 mg/ ml
hemangiol
pierre fabre medicament - propranolol hydroklorid - hemangiom - betablokkende midler - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.